$2.290
-0.030 (-1.29%)Al cierre
Noticias de LXRX
Eventos de LXRX
Lexicon Earns $10M Milestone Payment from Novo Nordisk
Lexicon (LXRX) announced that it has earned a third $10M milestone payment in 2026 from Novo Nordisk (NVO) following the achievement of a patient dosing milestone in the ongoing Phase 1 clinical development program for LX9851. LX9851 is being advanced by Novo Nordisk under the companies' exclusive worldwide license agreement signed in 2025. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. With the achievement of this milestone, Lexicon has now earned $75M of the $1B in potential upfront, development, regulatory and commercial milestone payments available under its collaboration with Novo Nordisk. In addition, Lexicon is entitled to receive tiered royalties on future net sales of LX9851.
Selling Stockholders Plan to Sell 1.26M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.26M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Lexicon Completes Patient Randomization in SOtaglifloziN Clinical Trial
Lexicon announced that randomization of patients has been completed in the pivotal Phase 3 "SOtaglifloziN in Patients with SymptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy" clinical trial evaluating sotagliflozin in patients with non-obstructive and obstructive hypertrophic cardiomyopathy. The study substantially exceeded its enrollment target of 500 patients across more than 130 sites in 20 countries
Company Reports Q1 Revenue of $21.1M, Exceeds Expectations
Reports Q1 revenue $21.1M, consensus $9.78M. Revenue for the quarter was driven by a $20M development milestone from Novo Nordisk and $1.1M in Inpefa net sales. "We have been intently focused on progressing our late and early-stage development pipeline in cardiometabolism and we are now well positioned to achieve several pivotal milestones as a result of those efforts," said CEO Mike Exton.
Lexicon Pharmaceuticals to Present Pilavapadin Study Results at AAN Meeting
Lexicon Pharmaceuticals announced that results from its Progress Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain, DPNP, supporting the selection of pilavapadin 10 mg as the optimal dose for Phase 3 development will be presented on Wednesday April 22, during the American Academy of Neurology, AAN, Annual Meeting. At the meeting, the company will also present results of an evaluation of pilavapadin on spasticity-related endpoints in preclinical models of multiple sclerosis and spinal cord injury. The congress is being held April 18-22 in Chicago, Illinois. In a session titled "Additional Efficacy Data Support Selection of Pilavapadin 10 mg for Phase 3 Development in DPNP: Results From PROGRESS," the company will present data from the study on pain outcomes as measured by the Brief Pain Inventory-Diabetic Peripheral Neuropathy patient reported instrument. Pilavapadin 10 mg achieved a nominally significant reduction in Average Pain at Week 8 versus placebo, with concordant improvements in Worst and Least Daily Pain, as measured by BPI-DPN. The 10 mg dose was generally well-tolerated over 8 weeks, with completion rates comparable to placebo and few discontinuations due to treatment emergent adverse events. Overall, these results provide additional support for the advancement of pilavapadin 10 mg into Phase 3 evaluation in DPNP.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.